Effect Of Medroxyprogesterone Acetate Research Articles

“Effects of Medroxy Progesterone Acetate (Inject-Able Contraceptive) on Diameter of Graffian Follicle (Ovary) of Adult Albino Rats”

Objective: An injectable birth control called Medroxy Progesterone Acetate (MPA) was used in the study to see how it affects adult female albino rats' ovaries. Study design An experimental study Place of study : To conduct the research, scientists worked with animals at the Dow University of Health Sciences' Animal House, the Institute of Basic Medical Sciences, and the Dow Diagnostic Research and Reference Laboratory (DDRRL). In the months of April and July of 2012, researchers conducted their investigation. Materials and Method:For the purpose of the research, a total of 72 female albino rats were chosen and divided into three distinct categories. Each group was further subdivided into three smaller groups based on the length of time that the therapy session lasted. The experiment utilized a group size of n = 24, which served as the control. The dose of MPA that was given to Group B (which consisted of 24 people) was 3 mg/kg of body weight. Participants in Group C (n = 24) were given an MPA dose that was two times higher than those in Group A (3 mg/kg). A single injection of MPA was given to group B as well as group C at the beginning of the experiment. During the course of the research, it was noticed that the ovaries of the animals had changed both in terms of their shape and their structure. Hematoxylin, eosin, and masson's trichrome were the stains that were used to color the tissues of the ovary. With the assistance of an ocular and stage micrometer, even minute differences could be detected and measured. The Kruskal-Wallis test and Tukey's test are two examples of nonparametric statistical analysis that were used to investigate the differences in each group's variables. Result: In comparison to control groups, experimental animals fed MPA had significantly smaller diameters of graafian follicles (DOF) than animals in the control groups. There was a significant difference in depth-of-field (DOF) between groups A1, B1, and C1 after one month of treatment. Groups A2, B2, and C2 each had a DOF of 571.25 98.26 meters, 288.25 100.80 meters, and 179.0 37.23 meters. In groups A3, B3, and C3, the DOF ranged from 699.75 m to 128.7 m, 230.37 m to 20.83 m, and 159.37 m to 47.65 m. Conclusion: Research shows that MPA can lower the amount of follicular atresia as well as chronic anovulation, according to the findings of this study. With this study's findings, we can better understand the risks that hormonal contraceptives like injections have to women's health. Keywords: MPA: Medroxy progesterone acetate FSH:Follicular Stimulating Hormone ,LH: Luteinizing Hormone. DOF : Diameter of graafian follicles

Study on Effects of Medroxyprogesterone Acetate on Serological Parameters, Ultrasonographic and Histopathological Profile of Uterine Endometrial Morphology in Female Rabbits

Background: Rabbits are small mammals from the family Leporidae. Rapid multiplication profile of the rabbits often necessitates contraceptive controls in which ovario-hysterectomy is the only recommended method worldwide but still rabbit owners avoid surgical manipulation and opt for the contraceptive injections but contraceptive injections are also known to cause undesired effects in different animal species. The present study was conducted to evaluate effects of Medroxyprogesterone acetate on liver enzymes, lipid profile, blood glucose and uterine endometrial morphology. Methods: The study was conducted on 20 breeding female rabbits at Pet Centre, University of Veterinary and Animal Sciences, Lahore, Pakistan. The study animals were divided into two groups, A and B having 10 rabbits each. Group A was treated with single dose of Medroxyprogesterone acetate (10 mg/kg IM). While group B was kept as control and was given a single dose of 0.9% normal saline placebo injection. Pre and post treatment serum sampling was performed on days 0, 7, 14, 21, 28, 35, 42 and histopathological evaluation of reproductive tract (mainly uterus) was conducted at the end of study. Result: Serological parameters i.e. liver profile, lipid profile and blood glucose level (random) were significantly increased after treatment along with congestion, engorgement of blood vessels, degeneration, hyperplasia of uterine epithelium and uterine glands in Treatment group in contrast to control group. On the basis of this study it was concluded that Medroxyprogesterone acetate poses undesirable effect on the uterine endometrium and different serological parameters of body like liver enzymes (total bilirubin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase), blood glucose, lipid profile (cholesterol, high density lipoprotein, low density lipoprotein, triglyceride).

The Effect of Medroxyprogesterone Acetate on the Secretion of Lipoprotein Lipase in Mouse Mammary Tumor Cells

The Effect of Medroxyprogesterone Acetate on the Secretion of Lipoprotein Lipase in Mouse Mammary Tumor Cells

Effects of medroxyprogesterone acetate on social behavior in female rhesus macaques (Macaca mulatta) depend on male breeding season introductions.

Although medroxyprogesterone acetate (MPA) is used commonly as a contraceptive in women and female non-human primates, its effects on social behavior remain unclear. This study examined whether MPA treatment and introduction of new adult males during the breeding season influence the social behaviors of group-housed adult female rhesus macaques. Subjects were 12 MPA-treated and 12 matched case-control females. Aggressive, affiliative, and sexual behaviors were measured. MPA-treated females showed less affiliative and sexual behavior compared to matched controls during the breeding season. MPA treatment was associated with decreased aggression emitted toward and received from females during the breeding season. MPA treatment is associated with differences in social behavior of female rhesus macaques during the breeding season, when normal hormonal cycles are attenuated by the treatment, but there is no indication that MPA-treated females bring an additional risk for more aggression during the male introduction and breeding season.

The effects of short-term medroxyprogesterone acetate on rut related behaviors, semen characteristics and fertility in farmed reindeer bulls

The effects of medroxyprogesterone acetate (MPA) on velvet antler cleaning, hypophagia, aggressive behavior and fertility were evaluated in farmed reindeer bulls during a 2-year study. Eight reindeer bulls aged 1–4 years were divided into 2 groups balanced for age. During each year, one group (MPA, n = 4) was treated with MPA 2 wk prior to the expected onset of rut while the other group (CTL, n = 4) served as untreated controls. Feed consumption, behavior and antler cleaning were recorded daily or 3 x weekly for 3 mo. Each year a dominant CTL and MPA bull were put into separate harems of estrous synchronized females for 1 wk in mid-September. Following harem breakup, semen was collected from all bulls via electroejaculation and evaluated. In Year 2 the bulls were switched such that year 1 MPA bulls received the CTL treatment and year 1 CTL bulls received MPA treatment. In Year 2 all eight bulls received MPA treatment/booster following semen collection. In both years, MPA treatment reduced rut associated body weight loss (p ≤ 0.05), rut associated hypophagia (p ≤ 0.001), interfered with velvet antler cleaning, and abolished aggressive rut related behavior. All of these changes suggest suppression of testosterone mediated effects. Alternatively, semen parameters differed little between treatment groups with the exception of reduced sperm concentration and total sperm production in MPA bulls (p ≤ 0.05). All CTL bulls in Year 2 exhibited full rut behavior with the dominant bull successfully breeding 100% of females available for breeding, suggesting no carryover effect of MPA treatment from the previous year. The MPA bull successfully bred 4 of 6 females (Year 1) but the MPA bull in Year 2 failed to sire any offspring. A single 400 mg treatment of MPA just prior to rut was sufficient to suppress rut associated aggression and hypophagia on a short-term (3 mo) basis. It did not however, completely suppress fertility.

Comparison of antiproliferative effects of metformine and progesterone on estrogen-induced endometrial hyperplasia in rats

Metformin has been shown to inhibit the growth of endometriotic implants, and reverse endometrial hyperplasia when combined with oral contraceptive in a case report. The aim of this study is to compare the antiproliferative effects of medroxyprogesterone acetate (MPA), and metformin in oopherectomized rat endometrium. Forty oopherectomized Wistar-Albino rats were used, and assigned to receive saline, 17 β Estradiol hemihydrate (4 mg/kg), 17 β Estradiol hemihydrate (4 mg/kg) and metformin (50 mg/kg), 17 β Estradiol hemihydrate (4 mg/kg) and MPA (1 mg/day) for 14 days. Histological markers of uterotrophy, including endometrial height, luminal ephitelial cell height and density of endometrial glands on hysterectomy speciments were quantified for each specimen. Rats treated with estradiol had significantly increased in endometrial height, endomerial luminal epithelial height and endometrial gland densitiy than the other groups. Metformin and MPA acetate significantly reduced all parameters indicating endometrial hyperplasia, and uterotrophy with respect to the control group. Antiproliferative effects of metformin, and MPA was found to be comparable for all three parameters. In conclusion, metformin attenuates estrogen-induced endometrial hyperplasia in ooferectomized rats to the same degree as progesterone.

Estrogen induces neurite outgrowth via Rho family GTPases in neuroblastoma cells

Estrogen (E2) has direct in vivo and in vitro effects, such as inducing neurite outgrowth, on neurons. We investigated the morphological changes and intracellular signaling pathway induced by E2 in neuroblastoma (SH-SY5Y) cells. The effect of medroxyprogesterone acetate (MPA) or progesterone (P4) on the E2-induced neurite outgrowth was also examined using SH-SY5Y cells. Neurite outgrowth was induced by E2 in association with the phosphorylation of Akt, and these effects of E2 were abolished by MPA but not by P4. Progesterone receptor antagonist RU486 blocked the inhibitory effects of MPA. Estrogen receptor antagonist ICI 182,780 and phosphatidylinositol 3-kinase inhibitor LY294002 inhibited the E2-induced neurite outgrowth. Because the Rho family of small GTPases has been shown to be involved in the regulation of neurite outgrowth, we examined the cross-talk among Rac1, Cdc42 and RhoA in the E2-induced neurite outgrowth. E2 immediately increased the Rac1 and Cdc42 activity and decreased the RhoA activity. E2-induced neurite outgrowth was attenuated in cells expressing dominant-negative mutants for Rac1 or Cdc42. These results suggest that regulation of Rho family GTPase activity by E2 is important for the neurite outgrowth in neuroblastoma cells, and that MPA may have an antagonistic effect against E2.

Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells

The purpose of this article is to determine the tumorigenic potential of estradiol treatment (E2) when combined with either progesterone (P4) or medroxyprogesterone acetate (MPA) in normal luminal human breast cells (HBE) and in human breast cancer cells (T47-D, MCF-7). Proliferation profiles were evaluated, along with the gene transactivation activity between the progesterone and glucocorticoid receptors (PR, GR) in HBE, T47-D, and MCF-7 cells treated by E2 + P4 or E2 + MPA. High throughput transcriptome analysis was performed on RNA from HBE cells treated by E2, E2 + MPA and E2 + P4. GR content was analyzed in normal breast cells as well. In HBE cells, E2 + P4 treatment was antiproliferative and promoted cellular differentiation. In contrast, E2 + MPA displayed mitogenic, antiapoptotic effects in HBE cells and did not influence cellular differentiation. The effect of P4 and MPA on cell proliferation was, however, variable in breast cancer cells. In cells containing GR or/and PR, MPA decreased proliferation whereas P4 antiproliferative effect needed the presence of PR. In HBE cells, the regulation of genes by E2 + P4, and E2 + MPA was significantly different, particularly in cell proliferation and cell death gene families. Further analysis revealed a modulation of the glucocorticoid receptor gene expression pathway by E2 + MPA. Predominant MPA glucocorticoid activity in normal and breast cancer cells was demonstrated using a glucocorticoid antagonist and the down-regulation of the GR by RNA interference. In normal luminal breast cells and in breast cancer cells, P4 and MPA combined with E2 treatment have opposing mitogenic effects due to GR. The consequences of MPA glucocorticoid potencies as well as the importance of GR in breast tissue merit a reappraisal.

The effects of medroxy progesterone acetate on the pro-inflammatory cytokines, TNF-alpha and IL-1beta in the early phase of the spinal cord injury

<title/>Objectives: Spinal cord injuries (SCIs) have high morbidity and mortality rates and currently the definitive treatment of complete SCIs are still not possible. We investigated the effects of the medroxy progesterone acetate on the pro-inflammatory cytokines, TNF-alpha and IL-1beta in the early phase of the SCI.Methods: Forty-eight Wistar albino male rats were divided equally into four groups each consisting of 12 rats. All animals underwent T10-T12 laminectomy. We administered placebo, and 8 mg/kg medroxy progesterone acetate (MPA) intra-peritoneally into control and progesterone group at 30 minutes after the clip-compression trauma in spinal cord. We performed only T10-T12 laminectomy and clip-compression trauma in laminectomy and trauma group, respectively. Half of the rats from each group were killed at 1 hour and the other half were killed at 6 hours after the trauma. Spinal cord segments were then removed and stored at −80°C in phosphate buffer. TNF-alpha and IL-1beta levels were determined using ELISA kit.Results: We have found that there was an increase only in the TNF-alpha level at 6 hours after the trauma comparing to control group. MPA appeared to lower the TNF-alpha level significantly in the trauma group.Discussion: This experimentally proven anti-inflammatory effect of MPA via acting upon TNF-alpha may offer new therapeutic options in human subjects with SCIs.

Effects of Medroxyprogesterone Acetate on Gene Expression in Myometrial Explants from Pregnant Women

Effects of Medroxyprogesterone Acetate on Gene Expression in Myometrial Explants from Pregnant Women

Effects of Medroxyprogesterone Acetate on Gene Expression in Myometrial Explants from Pregnant Women

Progesterone is important physiologically and therapeutically to maintain uterine quiescence during pregnancy, in part through controlling myometrial gene expression. The objective of the study was to use expression microarray and quantitative reverse transcriptase-PCR (qRT-PCR) validation to determine the changes in gene expression induced by prolonged exposure of human myometrium to a synthetic progestogen. Myometrial explants, obtained at elective cesarean section (n=9), were maintained in culture, under 0.6 g tension, for 65 h in the presence of medroxyprogesterone acetate (100 nm) or vehicle. Expression array was performed using Illumina beadchip arrays. Approximately 30% of differentially expressed transcripts were validated in biological replicates (n=10) by qRT-PCR. The 114 significantly regulated transcripts were significantly enriched in inflammatory response (P=0.00001), growth factor activity (P=0.0004), and cytokine activity genes (P=0.008). Thirty-four transcripts were validated using qRT-PCR in explants obtained from 10 further women. There was very close agreement in the fold changes obtained by array and qRT-PCR (r2=0.9, P<0.0001). We confirmed significant down-regulation of a number of genes that have been well characterized as progesterone sensitive (IL-1B, IL-6, PTGS2, and GJA1). However, the top and sixth most down-regulated transcripts encoded two cytokines, IL-11 and IL-24, respectively, not previously implicated in mediating the effects of progesterone in myometrium. Both were validated by qRT-PCR (4.3- and 2.2-fold down-regulated, both P<0.001). Medroxyprogesterone acetate controls expression of multiple genes in myometrium, including many that have not previously been characterized as progestogen regulated in this tissue, including IL-11 and IL-24. It is plausible that proteins encoded by some of these genes may have important but as yet uncharacterized effects in controlling human parturition.

Effects of Medroxyprogesterone Acetate on Gene Expression in Myometrial Explants from Pregnant Women

J Clin Endocrinol Metab, 10.1210/jc.2010-1541

Comparison of Selected Endocrine Parameters During Luteal Phase and Pregnancy in German Shepherd Dogs and Beagles

Concentrations of progesterone, prolactin and relaxin in serum at predetermined intervals after ovulation (day 0) in non-pregnant and pregnant normocyclic Beagles were assayed and results compared with those observed in German Shepherd dogs (GSD) in a previous study. The goal was to determine possible reproductive hormone specificities related to the GSD breed. Furthermore, the effects of medroxyprogesterone acetate (MPA)-treatment in non-pregnant Beagles and of progesterone supplementation in pregnant Beagles on the hormone concentrations were examined. Mean concentrations of progesterone and prolactin were not different in the non-pregnant Beagles compared with those seen in non-pregnant GSD, except at days 50-60, when progesterone concentrations were found to be higher in Beagles (p < 0.05). Mean progesterone concentrations in pregnant Beagles at days 50-60 after ovulation (day 0) were higher (p < 0.05) than in GSD at that time, but not at earlier time periods. Prolactin concentrations were higher (p < 0.05) in Beagles throughout pregnancy compared with those in the GSD. Mean relaxin concentrations were numerically but not significantly lower in GSD than in Beagles throughout pregnancy. A 10-day oral MPA treatment did not affect progesterone or prolactin secretion in normocyclic non-pregnant Beagles. Medroxyprogesterone acetate serum concentrations were approximately 3.9 ng/ml during treatment and decreased to 0.42 and 0.021 ng/ml within 5 and 15 days after end of treatment, respectively. Intramuscular progesterone supplementation from days 30 to 40 in pregnant Beagles resulted in higher concentrations of progesterone in the 36- to 45-day time periods; prolactin and relaxin concentrations were not significantly affected during or after treatment compared with administration of placebo. The results suggest a tendency towards deficient luteal function in the short-cycle GSD bitches previously studied, which in pregnancy may reflect the observed decreased prolactin concentrations; the possibility that GSD relaxin secretion is deficiency required needs further study. As oral treatment with MPA did not affect progesterone and prolactin release, it may be useful for studying luteal function in pregnant bitches with suspected hypoluteoidism.

Effects of Medroxyprogesterone Acetate on the Risk of Cardiovascular Disease in Postmenopausal Women Receiving Estrogen

Effects of Medroxyprogesterone Acetate on the Risk of Cardiovascular Disease in Postmenopausal Women Receiving Estrogen

Pulsatile plasma profiles of FSH and LH before and during medroxyprogesterone acetate treatment in the bitch

The aim of this study was to investigate the effect of medroxyprogesterone acetate (MPA) on pulsatile secretion of gonadotropins in the bitch. Five intact Beagle bitches were treated with MPA in a dose of 10mg/kg body weight subcutaneously at intervals of 4 weeks for a total of 13 injections, starting during anestrus. The 6-h plasma profiles of luteinizing hormone (LH) and follicle stimulating hormone (FSH) were determined before, and 3, 6, 9, and 12 months after the start of MPA treatment. After 6 months of MPA treatment basal plasma LH concentration was transiently increased significantly. Basal plasma FSH concentration and the area under the curve above the zero level (AUC0) for FSH were significantly higher after 3 months of MPA treatment than before or after 9 and 12 months of treatment. MPA treatment did not significantly affect pulse frequency, pulse amplitude, or AUC above the baseline for either LH or FSH. During treatment 58 significant LH pulses were identified, and although each LH pulse coincided with an increase in plasma FSH concentration, in 17 cases the amplitude of the increase was too small to be recognized as a significant FSH pulse. In conclusion, MPA treatment did not suppress basal plasma gonadotropin levels in the bitches. On the contrary, it caused a temporary rise in the basal concentration of both FSH and LH, which may have been due to a direct effect of MPA on the ovary. In addition, several LH pulses were not accompanied by a significant FSH pulse, suggesting that MPA treatment attenuated the pulsatile pituitary release of FSH.

3H-Thymidin-Inkorporation unter endokrinem Einfluß und Hormonrezeptorgehalt menschlicher Mammakarzinome

The effect of medroxyprogesterone acetate, oestradiol-17 beta and testolactone on 3H-thymidine incorporation in human mammary carcinoma was studied in vitro. 54% of the tumours reacted to medroxyprogesterone, while testolactone and oestradiol-17 beta changed 3H-thymidine incorporation in 45.1 and 41.3%, respectively. Both inhibition and the in vivo undesirable stimulation of 3H-thymidine incorporation was observed. No relation could be established between oestrogen receptor content and reaction of the mammary carcinoma to oestradiol-17 beta. On the other hand, the gestagen receptor content and the reaction of the mammary carcinoma to medroxyprogesterone acetate correlated significantly (P < 0.001). This underlines the increasing significance of the gestagen receptor in the selective endocrine treatment of mammary carcinoma.

Effects of medroxyprogesterone acetate on cerebral oedema and spatial learning performance after traumatic brain injury in rats

Background: Given after brain injury (TBI), progesterone reduces cerebral oedema and facilitates functional recovery. Progesterone analogues have been synthesized for use in many medical conditions and exhibit different chemical and biological properties. Medroxyprogesterone acetate (MPA) is widely used in clinical practice, but oestrogen/MPA combinations may increase the risk of stroke and cardiovascular disease rather than preventing them. In some conditions, MPA can exhibit pharmacological actions that are different from those of natural progesterone.Primary objective and hypothesis: Using laboratory rats, this study assessed the efficacy of MPA to determine whether this progestin and natural progesterone exert similar effects as a treatment after bilateral injury to the frontal cortex.Main outcomes and results: MPA produced a dose-related reduction of cerebral oedema at 48 hours post-TBI but neither 4 nor 16 mg/kg doses of MPA enhanced behavioural recovery.Conclusion: These findings help to clarify the divergent results from prior positive progesterone studies and the negative MPA clinical trials for hormone replacement therapy. The results can be taken to suggest that the control of cerebral oedema, while clearly desirable, is not the only contributor to progesterone-induced behavioural recovery.

Progesterone and Medroxyprogesterone Acetate Effects on Central and Peripheral Allopregnanolone and Beta-Endorphin Levels

The increased use of hormonal therapies has led to the study of the properties of different progestin molecules and their effects on the central nervous system. The central and peripheral levels of neurosteroid allopregnanolone and the opioid peptide β-endorphin (β-END) are regulated by estrogens. The aim of the present study was to investigate the effects of a 2-week oral treatment with micronized progesterone or medroxyprogesterone acetate (MPA) alone or in addition to estradiol valerate (E2V) on central and peripheral allopregnanolone and β-END levels in ovariectomized (OVX) female rats. Thirteen groups of Wistar OVX rats received one of the following treatments: oral progesterone (2, 4 or 8 mg/kg/day); oral MPA (0.05, 0.1 or 0.2 mg/kg/day); E2V (0.05 mg/kg/day); E2V + progesterone (0.05 mg/kg/day + 2, 4 or 8 mg/kg/day), or E2V + MPA (0.05 mg/kg/day + 0.05, 0.1 or 0.2 mg/kg/day) for 14 days. One group of fertile and one group of OVX rats were used as controls. The concentration of allopregnanolone was assessed in the frontal and parietal lobes, hypothalamus, hippocampus, anterior pituitary, adrenals and serum, while the β-END content was assessed in the frontal and parietal lobes, hypothalamus, hippocampus, anterior and neurointermediate pituitary, and plasma. E2V administration reverted the ovariectomy-induced reduction in allopregnanolone and β-END. Progesterone and MPA increased allopregnanolone levels in all tissues except in the adrenal gland. The combined administration of progesterone or MPA and E2V determined a further increase in allopregnanolone levels with respect to E2V alone except in the adrenal gland and hippocampus only after MPA treatment. Progesterone did not affect β-END levels in the frontal and parietal lobes, hippocampus and anterior pituitary, while it caused an increase plasma, hypothalamic and neurointermediate pituitary β-END levels. MPA only affected β-END levels in the hippocampus and in the neurointermediate lobe. The combined administration of progesterone or MPA and E2V did not alter the effect of estradiol or it determined a further dose-dependent increase in β-END levels. In conclusion, this study demonstrates that progesterone and MPA have a similar but not identical effect on central and peripheral allopregnanolone and β-END levels. Their association with an estrogenic compound does not interfere with the positive effects produced by estrogen on allopregnanolone and β-END brain content.

The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits – an attempt to interpret the Women's Health Initiative results

The results of the two arms of the Women's Health Initiative (WHI) study allow a comparative assessment of the contribution of the progestogen component to the changes in risk of cardiovascular disease and cancer during treatment of postmenopausal women with conjugated equine estrogens and medroxyprogesterone acetate (CEE/MPA). However, the high proportion of older and overweight or obese women compromises any conclusions, since we estimate that 50% of the women would have the metabolic syndrome. In overweight postmenopausal women with hyperinsulinemia, the risk of breast cancer is elevated and cannot be increased further by hormone replacement therapy (HRT). Therefore, the non-significant, but consistent reduction in breast cancer risk during treatment with CEE alone might be based on an improvement of hyperinsulinemia. The 24% increase in breast cancer risk in the CEE/MPA group can be regarded as an artifact due to very low numbers of breast cancer diagnoses in the placebo group of women who had received HRT prior to the WHI study. The elevated risk of venous thromboembolism and the transient increase in the risk of coronary heart disease (CHD) during treatment with CEE/MPA but not CEE alone suggests a direct effect of MPA on the vessel wall. MPA has been demonstrated to upregulate the thrombin receptor, the thrombin-induced production of tissue factor and procoagulatory activity in the vessel wall owing to its glucocorticoid activity. In contrast, CEE alone reduced non-significantly the risk of CHD in women aged 50–59 years, suggesting that primary prevention is possible if estrogen replacement therapy is initiated early. As clinical studies on the effect of different progestogens combined with estrogens are scarce, a possible superiority of progestogens other than MPA remains to be proven.

Combination of chemotherapy with medroxyprogesterone acetate improves the quality of life in patients with advanced cancer

目的 观察晚期癌症患者服用甲孕酮后改善化疗所致毒副反应,及止痛和促进蛋白同化的作用.方法 66例晚期癌症患者随机分为化疗+甲孕酮组及单用化疗组.结果并用甲孕酮组34例患者82.4%(28/34)进食量增加,78.2%(26/34)体重增加,平均血浆白蛋白增加(1.3±2.7)g/L,血红蛋白增加(3.1±1.6)g/L,35.3%(12/34)ECOG改善,88.8%患者疼痛减轻,化疗的毒副反应按WHO化疗药物急性毒性分级标准,Ⅱ度以上血红蛋白下降发生率12.5%,白细胞下降发生率37.5%,胃肠道反应18.8%,平均恢复天数分别为(4.6±3.3)d、(6.6±3.7)d、(2.4±1.3)d,以上各项指标与单用化疗组相比差异有显著意义.结论甲孕酮用于晚期癌症的治疗,可以改善化疗期间癌症患者的生活质量。